Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.
Impacto
Scholar |
Otros documentos de la autoría: Núñez, Julio; Palau, Patricia; Domínguez Mafé, Eloy; Mollar, Anna; Núñez, Eduardo; Ramón, José María; Miñana, Gema; Santas, Enrique; Facila Rubio, Lorenzo; Górriz, José Luis; Sanchis, Juan; Bayes-Genis, Antoni
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONEste recurso está restringido
https://doi.org/10.1002/clc.22899 |
Metadatos
Título
Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.Autoría
Fecha de publicación
2018-04-17Editor
WileyCita bibliográfica
NUÑEZ, Julio; PALAU SAMPIO, Patricia; DOMÍNGUEZ MAFÉ, Eloy; MOLLAR, Anna; NUÑEZ, Eduardo; RAMÓN, José María; MIÑANA, Gema; SANTAS, Enrique; FÁCILA, Lorenzo; GÓRRIZ, José L.; SANCHIS, Juan; BAYÉS-GENÍS, Antoni, (2018). Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. Clinical Cardiology, v. 41, issue 4, p. 476-480Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
https://onlinelibrary.wiley.com/doi/abs/10.1002/clc.22899Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Background: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising ther-
apy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM).
However, there is a ... [+]
Background: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising ther-
apy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM).
However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to eval-
uate the short-term effects of empagliflozin on maximal exercise capacity in these patients.
Hypothesis: We postulate tretament with empagliflozin may improve functional capacity in
patients with T2DM and established HF.
Methods: Nineteen T2DM patients with symptomatic HF were prospectively included and
underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflo-
zin therapy. A mixed-effects model for repeated measures was used.
Results: Median patient age was 72 years (interquartile range, 60–79 years); 42.1% were in
New York Heart Association class III. Baseline mean ( SD) peak oxygen consum ption (peak VO
2
)
was 10.9 4. 0 mL/ min /k g. P eak VO
2
increased significantly at 30 days (∆: +1.21 [0.66 to 1.76]
mL/min/kg; P < 0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute
walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found.
Estimated glomerular filtration rate and natriuretic peptides did not significantly change.
Conclusions: In this pilot study, empagliflozin was associated with 1-month improvement in
exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found
for other surrogates of severity. [-]
Proyecto de investigación
This work was supported in part by grants from CIBER Cardiovascular (16/11/00420, 16/11/00403), FEDER, and PIE (15/00013).Derechos de acceso
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/restrictedAccess
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- MED_Articles [667]